Last time I posted about CAPRICOR, it was at $5.50/share, now trading at $19. It has a 50% haircut from it's ATH from the last short-squeeze in November upon positive readout. Here we are again, sure, a higher entry point, but even more upside in less than 30 days. $CAPR is about to have its final FDA meetings heading into the August 22 FDA approval date. Short interest has climbed all the way back to 30% from where it was in November before the Shorts got crushed. They just signed a long-ter
CryptoAlerta — análise de criptomoedas e mercado em tempo real